Results for astrazeneca: 46

WASHINGTON, March 30 - AstraZeneca Plc's cancer pill Recentin, developed to be a rival to the blockbuster Avastin, may help fight the deadly effects of brain tumors without shrinking them, researchers reported on Monday. They...

* AstraZeneca eyes Symbicort as rival to Glaxo's Advair * Symbicort is approved for moderate-to-severe COPD * Drug does not replace fast-acting inhalers WASHINGTON, Feb 27 - U.S. health regulators have approved AstraZeneca Plc's asthma...

AstraZeneca and Bristol-Myers Squibb (BMS) recently announced the expansion of their worldwide collaboration to include the development and commercialisation of...

astraZeneca has entered into a settlement agreement in its pulmicort respules patent infringement litigation against Ivax Pharmaceuticals, Inc, a wholly owned subsidiary of Teva Pharmaceuticals USA...

LONDON, Sept 23 - AstraZeneca expects sales of pharmaceuticals in developed markets to turn negative by early next decade as a slew of patents on blockbuster drugs expire, making emerging markets crucial to long-term growth...

* Lundberg to replace retiring Lilly R&D head Paul * Quitting Astra immediately, will join Lilly in new year NEW YORK, Nov 13 - Eli Lilly and Co has snagged AstraZeneca Plc's head of drug...

WASHINGTON, July 31 - AstraZeneca PLC and Bristol-Myers Squibb Co won U.S. approval on Friday to sell a new diabetes drug called Onglyza. The Food and Drug Administration said it was requiring a post-approval study...

SILVER SPRING, Md., April 8 - AstraZeneca PLC won partial support from U.S. advisers on Wednesday for its bid to expand the approved uses of a blockbuster schizophrenia drug. A committee of Food and Drug...

SILVER SPRING, Md., April 8 - AstraZeneca Plc's Seroquel XR schizophrenia drug is safe enough for treating some patients with depression, a U.S. advisory panel said on Wednesday. The committee of Food and Drug Administration...

* AstraZeneca accuses Apotex of patent infringement * Files suit over generic of asthma drug in U.S. court * Pulmicort Respules had 2008 U.S. sales of $982 mln NEW YORK, April 3 - AstraZeneca Plc...